Diagnostic Utility of F-18 Florbetapir PET/MR in Peripheral Nerve Amyloidosis

Completed · Phase 1/Phase 2

Conditions studied: Amyloidosis

In brief

The primary aim of this study will be to examine the diagnostic utility of 18-F Florbetapir PET/MR (Positron Emission Tomography/Magnetic Resonance) in imaging patients with pathologically-confirmed systemic amyloidosis involving the peripheral nerves and compare these results to non-amyloid diseased controls.

Key facts

Study ID

NCT03019029

Run by

Mayo Clinic

People needed

8

Starts

2017-03-13

Expected to finish

2022-03-24

Last updated by the study team

2026-03-16

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adults: 18-100
• Pathologically-confirmed peripheral nerve amyloidosis or pathologically-confirmed non-amyloid causes of peripheral neuropathy

You may not qualify if…

• Metallic devices that are not MR safe (cardiac pacers, stents, aneurysm coils, etc.)
• Claustrophobia
• BMI over 38

Where it is running

• Mayo Clinic in Rochester — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.